# Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

Study · id `cardio:ct-nct01644474` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01644474](<https://clinicaltrials.gov/study/NCT01644474>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01644474

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT01644474. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2015-11-06.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT01644474, source copy `cardio:ctgov-nct01644474-2015-11-06`, retrieved 2026-10-31)
- Start date: 2012-07 (registry gives no type) (ClinicalTrials.gov record NCT01644474, source copy `cardio:ctgov-nct01644474-2015-11-06`, retrieved 2026-10-31)
- Primary completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01644474, source copy `cardio:ctgov-nct01644474-2015-11-06`, retrieved 2026-10-31)
- Completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01644474, source copy `cardio:ctgov-nct01644474-2015-11-06`, retrieved 2026-10-31)
- Results first posted: 2015-11-06 (ClinicalTrials.gov record NCT01644474, source copy `cardio:ctgov-nct01644474-2015-11-06`, retrieved 2026-10-31)
- Countries: United States; Belgium; Finland; Netherlands (ClinicalTrials.gov record NCT01644474, source copy `cardio:ctgov-nct01644474-2015-11-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01644474-2015-11-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
- Acronym: ODYSSEY MONO
- Condition: Hypercholesterolemia
- Intervention (Drug): Alirocumab
- Intervention (Drug): Ezetimibe
- Intervention (Drug): Placebo (for Alirocumab)
- Intervention (Drug): Placebo (for Ezetimibe)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial (`cardio:pubmed-25037695`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks (`cardio:pubmed-25606700`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 224fb9533e05bba90a883cc19fdfa48e7d1473f708f2e0b016644cbeb6e806b9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
